Biomarker ID | 704 |
PMID | 21822036 |
Year | 2011 |
Biomarker | Methylation Status of RARB |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Urine |
Subjects | Humans |
Regulation | Hypermethylated in Gleason Score 7 (PMR>=50) |
Odds Ratio/Hazard Ratio/Relative Risk | OR, 40.0; (95% CI, 2.0–794.9) |
Effect on Pathways | Pathways Include:-Non-small cell lung cancer,Vitamin A and carotenoid metabolism,Nuclear receptor transcription pathway,Nuclear receptors,Small cell lung cancer |
Experiment | Gleason Score 6 Vs Gleason Score 7 |
Type of Biomarker | Prognostic |
Cohort | 34 patients with untreated prostate cacner were selected, The cases were diagnosed with early- (pT2, n=21) or medium-stage (pT3, n=13) prostate carcinoma of score 6 (n=24) or 7 (n=10). From this cohort, 32 cases were available |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | 44% |
Level Of Significance | p=0.01 |
Method Used | Real-time methylation-specific PCR |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | RARB |